The UK Medicines and Healthcare products Regulatory Agency (MHRA) is advising healthcare professionals that there is a risk of potentially harmful drug interactions with the ritonavir component of the COVID-19 treatment Paxlovid (nirmatrelvir+ritonavir) due to its inhibition of the enzyme CYP3A4, which metabolises many commonly used drugs and may lead to increased toxicity from concomitant medications or reduced effectiveness of Paxlovid. …
Anzeige
Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten